Drug development consultancy KLIFO expands to the Netherlands

KLIFO A/S has acquired MediServ, a life science company based in the Netherlands. MediServ provides life science services to pharmaceutical, medical device and biotech companies and the company’s services include clinical research and regulatory affairs. With this acquisition, KLIFO now has offices in four core locations in Europe.

17 February 2021


The Netherlands is a top country in Europe for export and import of medical devices and holds the eighth position worldwide for patent applications in the field of life sciences and health. This, together with the proximity of MediServ to the European Medicines Agency (EMA) and its established operational base in Belgium, will bolster KLIFO’s ability to provide its clients with even more targeted solutions to help them progress in their drug development journeys. “KLIFO and MediServ have collaborated over several years through PSN Research which both companies have been partners and shareholders in. So, it seems only natural to integrate the MediServ team into the KLIFO family, now that the opportunity has arisen,” explains Alejandra Mørk, chief executive officer for KLIFO.


KLIFO is an established and integrated drug development
consultancy providing both consulting and operational services
in all areas of drug development to pharmaceutical and biotech
companies. KLIFO was established in 1994 and is headquartered
in Denmark with affiliate offices in Munich, Germany, Lund,
Sweden and now Eindhoven, the Netherlands. KLIFO has more
than 150 highly skilled staff. KLIFO will leverage the current
capacity and expertise within MediServ to expand on its own
service offering for existing and new clients and MediServ will be
able to draw on KLIFO’s broad range of drug development